This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harada, H. Articles by Kizaka-Kondoh, S. Search for Related Content PubMed PubMed Citation Articles by Harada, H. Articles by Kizaka-Kondoh, S.

Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells

Pharmaceuticals Division, Pharmaceutical R&D Department, POLA Chemical Industries, Inc., Totsuka-ku, Yokohama 244-0812 [H. H.]; Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507 [M. H.]; and Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501 [S. K-K.], Japan

Human solid tumors contain hypoxic regions that have considerably lower oxygen tension than normal tissues. These impart resistance to radiotherapy and anticancer chemotherapy, as well as predisposing to increased tumor metastases. To develop a potentially therapeutic protein drug highly specific for solid tumors, we constructed fusion proteins selectively stabilized in hypoxic tumor cells. A model fusion protein, oxygen-dependent degradation (ODD)-ß-galactosidase (ß-Gal), composed of a part of the ODD domain of hypoxia-inducible factor-1 fused to ß-Gal, showed increased stability in cultured cells under a hypoxia-mimic condition. When ODD-ß-Gal was further fused to the HIV-TAT protein transduction domain (TAT_47–57) and i.p. injected to a tumor-bearing mouse, the biologically active fusion protein was specifically stabilized in solid tumors but was hardly detected in the normal tissue. Furthermore, when wild-type (WT) caspase-3 (Casp3^WT) or its catalytically inactive mutant was fused to TAT-ODD and i.p. injected to a tumor-bearing mouse, the size of tumors was reduced by the administration of TAT-ODD-Casp3^WT but not by TAT-ODD-mutant Casp3. TAT-ODD-Casp3^WT did not cause any obvious side effects on tumor-bearing mice, suggesting specific stabilization and activation of the fusion protein in the hypoxic tumor cells. These results suggest that the combination of protein therapy using a cytotoxic TAT-ODD fusion protein with radiotherapy and chemotherapy may provide a new strategy for annihilating solid tumors.

This article has been cited by other articles:

				T. Hiraga, S. Kizaka-Kondoh, K. Hirota, M. Hiraoka, and T. Yoneda Hypoxia and Hypoxia-Inducible Factor-1 Expression Enhance Osteolytic Bone Metastases of Breast Cancer Cancer Res., May 1, 2007; 67(9): 4157 - 4163. [Abstract] [Full Text] [PDF]

				K. Mani, S. Sandgren, J. Lilja, F. Cheng, K. Svensson, L. Persson, and M. Belting HIV-Tat protein transduction domain specifically attenuates growth of polyamine deprived tumor cells Mol. Cancer Ther., February 1, 2007; 6(2): 782 - 788. [Abstract] [Full Text] [PDF]

				N. Koshikawa and K. Takenaga Hypoxia-Regulated Expression of Attenuated Diphtheria Toxin A Fused with Hypoxia-Inducible Factor-1{alpha} Oxygen-Dependent Degradation Domain Preferentially Induces Apoptosis of Hypoxic Cells in Solid Tumor Cancer Res., December 15, 2005; 65(24): 11622 - 11630. [Abstract] [Full Text] [PDF]

				K. Hirota, R. Fukuda, S. Takabuchi, S. Kizaka-Kondoh, T. Adachi, K. Fukuda, and G. L. Semenza Induction of Hypoxia-inducible Factor 1 Activity by Muscarinic Acetylcholine Receptor Signaling J. Biol. Chem., October 1, 2004; 279(40): 41521 - 41528. [Abstract] [Full Text] [PDF]

				Y. Nishinaka, A. Nishiyama, H. Masutani, S.-i. Oka, K. Md. Ahsan, Y. Nakayama, Y. Ishii, H. Nakamura, M. Maeda, and J. Yodoi Loss of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 in Human T-Cell Leukemia Virus Type I-Dependent T-Cell Transformation: Implications for Adult T-Cell Leukemia Leukemogenesis Cancer Res., February 15, 2004; 64(4): 1287 - 1292. [Abstract] [Full Text] [PDF]

				K. Kasuno, S. Takabuchi, K. Fukuda, S. Kizaka-Kondoh, J. Yodoi, T. Adachi, G. L. Semenza, and K. Hirota Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent on MAPK and Phosphatidylinositol 3-Kinase Signaling J. Biol. Chem., January 23, 2004; 279(4): 2550 - 2558. [Abstract] [Full Text] [PDF]